

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

|                        |                     |
|------------------------|---------------------|
| Application Number     | 10/530,176          |
| Filing Date            | March 9, 2006       |
| First Named Inventor   | Graham Edmund KELLY |
| Art Unit               | 1612                |
| Examiner Name          | Benjamin J PACKARD  |
| Attorney Docket Number | Q86664              |

## U.S. PATENTS

| Examiner Initials* | Cite No | Patent Number | Kind Code <sup>1</sup> | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|---------|---------------|------------------------|------------|---|---|
|                    | 1       |               |                        |            |   |   |

## U.S. PATENT APPLICATION PUBLICATIONS

| Examiner Initials* | Cite No | Publication Number | Kind Code <sup>1</sup> | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|---------|--------------------|------------------------|------------------|---|---|
|                    | 1       |                    |                        |                  |   |   |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No | Foreign Document Number <sup>3</sup> | Country Code <sup>2</sup> | Kind Code <sup>4</sup> | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T <sup>5</sup>           |
|--------------------|---------|--------------------------------------|---------------------------|------------------------|------------------|---|---|--------------------------|
|                    | 1       | 03/086386                            | WO                        | A1                     | 2003-10-23       | Novogen REsearch Pty., Ltd.                     |   |                          |
|                    | 2       | 01/17986                             | WO                        | A1                     | 2001-03-15       | Novogen Research Pty., Ltd.                     |   |                          |
|                    | 3       | 98/08503                             | WO                        | A1                     | 1998-03-05       | Kelly, G.                                       |   |                          |
|                    | 1       | 00/03707                             | WO                        | A1                     | 2000-01-27       | Laboratoire L. Lafon                            |   | Corresponds to CN1312712 |
|                    | 4       | 1312712                              | CN                        | A                      | 2001-09-12       | Laboratoire L. Lafon                            |   | Corresponds to WO0003707 |

## NON-PATENT LITERATURE DOCUMENTS

|                    |         |  |                |
|--------------------|---------|--|----------------|
| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published. | T <sup>5</sup> |
|                    | 1       | Abstract XP002541865, "Phenoxodiol enters phase II leukemia trial", DailyDrugNews.com (Daily Essentials), September 26, 2002   | Abstract only  |
|                    | 2       | ANDREAS I. CONSTANTINO, et al., "Phenoxodiol (2H-1-Benzopyran-7-O,1,3-(4-hydroxyphenyl)), A Novel Isoflavone Derivative, Inhibits DNA Topoisomerase II by Stabilizing the Cleavable Complex", Anticancer Research, Vol. 22, No. 5, pp. 2581-2586, September 2002 |                |
|                    | 3       | TITO FOJO, et al., "Taxol and other microtubule-interactive agents", Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs, Vol. 2, No. 3, pp. 293-304, January 1, 2000  |                |
|                    | 4       | DIRK TH. SLEIJFER, et al., "Cisplatin: a review of clinical applications and renal toxicity", Pharmaceutish Weekblad Scientific Edition, Vol. 7, No. 6, pp. 237-244, December 13, 1985   |                |
|                    | 5       | ANTONA J. WAGSTAFF, et al., "Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer", Drugs, Vol. 37, No. 2, pp. 162-190, February 1989                                     |                |
|                    | 6       | Supplemental European Search Report dated September 4, 2009, issued in European Application No. 03798829.2   |                |

## EXAMINER SIGNATURE

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.